Epic Sciences' $40 Million D Round Led by Hermed Capital of Hong Kong

Epic Sciences of San Diego closed a $40 million Series D financing led by Hong Kong's Hermed Capital. Epic is developing a portfolio of blood-based tests that predict drug response in cancer. Its most advanced product, the OncotypeDx AR-V7 Nucleus Detect test, helps physicians decide whether taxane chemotherapy or targeted therapies are the better treatment for metastatic castration-resistant prostate cancer. Hermed intends to help Epic bring its product(s) to China. More details.... Share this with colleagues: // //